Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1676
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2498
    -0.0013 (-0.11%)
     

  • Bitcoin GBP

    51,182.26
    -525.45 (-1.02%)
     

  • CMC Crypto 200

    1,333.93
    -62.61 (-4.48%)
     

  • S&P 500

    5,108.72
    +60.30 (+1.19%)
     

  • DOW

    38,288.38
    +202.58 (+0.53%)
     

  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     

  • GOLD FUTURES

    2,351.20
    +8.70 (+0.37%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?

Keith Speights and Brian Orelli, PhD, The Motley Fool
·3-min read

In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).

Continue reading